Compare Medpace Holdings Inc (MEDP) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard International High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| MEDP | VYMI | |
|---|---|---|
Market Cap | $16.82B | $22.80B |
Volume | 223,093 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $107.13 |
52-Week Low | $393.42 | $82.92 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
VYMI trades at $100.06, down 0.17% with bearish technical signals from moving averages. The ETF shows strong institutional interest with recent stake increases from Envestnet and Corient Private Wealth. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with lower fees. The fund's heavy financial sector exposure (43.6%) benefits from rising global interest rates.
VYMI presents a compelling international dividend growth opportunity with attractive valuation and income characteristics. Key risks include concentration in financials and sensitivity to global economic conditions. The ETF's low 0.07% expense ratio and strong historical performance support its appeal for income-focused investors seeking international diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
